Journal of Cardiovascular SurgeryISSN 2095-2260 CN 11-9317/R 联系我们网站地图帮助中心

您的位置:首页>> 文章摘要


逯若逸 宋元申 韩宏光

121000 辽宁锦州,锦州医科大学研究生院15级(逯若逸、宋元申);沈阳军区总医院心外科(韩宏光)


摘 要:心力衰竭(HF)是由于心脏泵功能出现异常而发生的严重临床症状,通常表现为肺水肿引起的呼吸困难、单心室或双心室的充血性 HF、心源性休克。心脏术后急性HF患者心功能差,预后不佳,因此合理的用药和精心的处理尤为重要。正性肌力药物可避免多脏器功能衰竭的 发生。正性肌力药可单一也可以联合使用,但目前尚缺乏在心脏术后HF中应用的专家共识与随机对照试验。随着β受体阻滞剂和盐皮质激素受 体拮抗剂(MRA)、血管紧张素受体阻滞剂(ARB)、血管紧张素转移酶抑制剂(ACEI)等药物的出现,心脏术后合并HF的药物治疗取得了重要 进展。本文就新研发的抗HF药物作用机制及其研究进展作一综述。

关键词:心脏外科手术; 心力衰竭; 药物疗法; 作用机制

评论   收藏 全文阅读: FullText | PDF

文献标引:逯若逸 宋元申 韩宏光.心脏术后心力衰竭的药物治疗作用机制[J/CD].心血管外科杂志:电子版,2016,5(2):33.

[1] McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic

heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European

Society of Cardiology. Developed in collaboration with the Heart Failure Association(HFA) of the ESC. Eur Heart J, 2012, 33:

[2] McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl

J Med, 2014, 371: 993-1004.
[3] Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol, 2007, 50: 2357-2368.
[4] Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with

preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet, 2012, 380: 1387-1395.
[5] Packer M, McMurray JJ, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the

risk of clinical progression in surviving patients with heart failure. Circulation, 2015, 131: 54-61.
[6] Zannad F, Gattis Stough W, Rossignol P, et al. Mineralocorticoid receptor antagonists for heart failure with reduced

ejection fraction: integrating evidence into clinical practice. Eur Heart J, 2012, 33: 2782-2795.
[7] Butler J, Ezekowitz JA, Collins SP, et al. Update on aldosterone antagonists use in heart failure with reduced left

ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. J Card Fail, 2012, 18: 265-281.
[8] Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J

Med, 2011, 364: 11-21.
[9] Desai AS, Lewis EF, Li R, et al. Rationale and design of the treatment of preserved cardiac function heart failure

with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart

failure and preserved ejection fraction. Am Heart J, 2011, 162: 966-972.
[10] Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J

Med, 2014, 370: 1383-1392.
[11] Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved

Cardiac Function Heart Failure With an Aldosterone Antagonist(TOPCAT) trial. Circulation, 2015, 131: 34-42.
[12] Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N

Engl J Med, 2012, 367: 2204-2213.
[13] Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N

Engl J Med, 2013, 369: 1892-1903.
[14] Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS

inhibitors. N Engl J Med, 2015, 372: 211-221.
[15] Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium

binder, in a double-blind, placebocontrolled study in patients with chronic heart failure(the PEARL-HF) trial. Eur Heart J,

2011, 32: 820-828.
[16] Stavros F, Yang A, Leon A, et al. Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS

One, 2014, 9: e114686.
[17] Ash SR, Singh B, Lavin PT, et al. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney

disease suggests that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int, 2015, 88: 404-411.
[18] Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med, 2015, 372:

[19] Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28

days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA, 2014, 312: 2223-2233.
[20] Anker SD, Kosiborod M, Zannad F, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate(ZS-9) in

heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail, 2015,

17: 1050-1056.
[21] Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure(SHIFT): a randomised placebo

-controlled study. Lancet, 2010, 376: 875-885.
[22] Böhm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure(SHIFT): the association

between heart rate and outcomes in a randomised placebo-controlled trial. Lancet, 2010, 376: 886-894.
[23] Borer JS, Böhm M, Ford I, et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in

patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J, 2012, 33: 2813-2820.
[24] Ekman I, Chassany O, Komajda M, et al. Heart rate reduction with ivabradine and health related quality of life in

patients with chronic heart failure: results from the SHIFT study. Eur Heart J, 2011, 32: 2395-2404.
[25] Du XJ, Bathgate RA, Samuel CS, et al. Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat

Rev Cardiol, 2010, 7: 48-58.
[26] Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure(Pre-RELAX-

AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase Ⅱb study. Lancet, 2009, 373: 1429-

[27] Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart

failure(RELAX-AHF): a randomised, placebo-controlled trial. Lancet, 2013, 381: 29-39.
[28] Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin

in Acute Heart Failure(RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol, 2013, 61: 196-206.
[29] Potter LR, Yoder AR, Flora DR, et al. Natriuretic peptides: their structures, receptors, physiologic functions and

therapeutic applications. Handb Exp Pharmacol, 2009: 341-366.
[30] Dontas ID, Xanthos T, Dontas I, et al. Impact of nesiritide on renal function and mortality in patients suffering

from heart failure. Cardiovasc Drugs Ther, 2009, 23: 221-233.



曹先招 马 捷. .心血管外科杂志:电子版 2016;5(2):24.

摘要 FullText PDF 评论 收藏


宋元申 逯若逸 韩宏光. .心血管外科杂志:电子版 2016;5(2): 29.

摘要 FullText PDF 评论 收藏


逯若逸 宋元申 韩宏光. .心血管外科杂志:电子版 2016;5(2):33.

摘要 FullText PDF 评论 收藏


常忠路 毕研文. .心血管外科杂志:电子版 2016;5(2):38.

摘要 FullText PDF 评论 收藏